Topic Archives: immunotherapy

Mizrahi’s “World’s Top Billionaires Invest in the Biggest Cancer Breakthrough Since Chemo”

There’s a clear winner in the “what readers are asking about” sweepstakes this morning, and it’s the latest pitch from Charles Mizrahi for his Park Avenue Investment Club (currently $99/yr) — so that ad must really be making the rounds, and we’ll fire up the Thinkolator to get you some answers today. The pitch is […]

Skousen’s “must have” cancer killer stock… and it’s “one of the world’s oldest, publicly traded companies”

This is a combo you don’t hear about very often, “founded in the 17th century” and “cancer killing blockbuster” … usually, the little biotechs that newsletters drop hints about are tiny, young, risky, sometimes fly-by-night outfits that are betting it all on a clinical breakthrough. Not this time, apparently. So that’s why my eye was […]

Ray Blanco’s $1 Cancer Tease: “I Predict This Man Will Win The Nobel Prize… It Could Also Hand You an Empire of Wealth”

Another biotech teaser for you today — these never seem to stop, perhaps partly because small biotech stocks are almost the only ones, other than little junior miners, that have a legitimate chance of seeing their prospects change dramatically overnight or see rapid 100%, 200%, 500% share price gains on a new discovery or shockingly […]

Comments

  • Gr8Full!

    $XCUR calendar of upcoming events: http://investors.exicuretx.com/phoenix.zhtml?c=254193&p=irol-calendar Upcoming ...

  • Gr8Full!

    #History > Immunotherapy: Revolutionizing Cancer Treatment since 1891 https://www.mskcc.org/blog/immunotherapy-revoluti...

  • Avatar

    I like MRK and PFE for the next 12 months in my steady as she goes account.But, for big potential I am in the speculativ...

  • Michael Jorrin,

    That depends on what you mean by "movers and shakers." I try to keep abreast of what's going on in the research areas ...

  • Gr8Full!

    New approach to #immunotherapy leads to complete response in bre ast cancer patient https://medicalxpress.com/news/201...

  • Avatar

    The most beneficial cellular targets will be cell-types that regularly divide. This includes epithelium, or surface tiss...

  • Gr8Full!

    $Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Pr...

  • Gr8Full!

    $CLLS, $PFE 20183018-21 > Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the ...

  • Gr8Full!

    Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells https://www.nature.com/...

  • Gr8Full!

    $BGNE has a new IDO1 inhibitor (BGB-5777) that they are claiming has greater BBB penetration than the $INCY compound. He...

  • Gr8Full!

    $$HTBX fp - #OpposableThumb a forward? say 3:1 :-) *UPDATE: Heat Biologics Says 'Overall responses appeared durabl...

  • Gr8Full!

    #SRNE ow - Restated financials for NANT investment ed to changes for impaimetn charge: The number of shares of the iss...

  • Gr8Full!

    Keep the $FATE :-) February 23, 2018 8:00 AM EST Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Transl...

  • Avatar

    $PIRS np Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th BOSTON, MA--(Marketwired - J...

  • Avatar

    SRNE-NP- company Doc talked fondly of yesterday and former shareholder. Lurking with this company with its leading antib...

  • Avatar

    $ONCS - long I still own ONCS. I'm very interested in hearing more of the bear argument. In truth, I'm low on portfo...

  • Avatar

    $SRNE Long From January 16th Sorrento Therapeutics target raised to $30 at H.C. Wainwright -- Multiple Recent De...

  • Dr. KSS MD PhD

    Trading notices: Exit $DFFN.....had starter position, but don't feel company holding up under due diligence Exit $...

  • Avatar

    $ATNM long tyler_l45. So with CAR-T, it is antibody specific also. I am pasting from a cancer network website -"Ultim...

  • Avatar

    $INO UW Inovio and Parker Institute announce clinical collaboration agreement Inovio Pharmaceuticals and the Parker...

  • Avatar

    I wonder if these comments are from the real Myron Martin or an impostor. I say that because I believe that I have read...

  • Dr. KSS MD PhD

    I have been on the phone with them today trying to arrange a time to visit corp HQ. Working on it. This is a very intell...

  • SoGiAm

    $AFMD fp - (long) Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Comple...

  • SoGiAm

    #Moderation Please! $FATE long – Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells fro...

  • SoGiAm

    $FATE long - Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal Engineered Ma...

  • SoGiAm

    The cancer immunotherapy pipeline is overcrowded; $SAGE, Roche $RHBBY, Spark $ONCE tout big advances https://endpts.co...

  • SoGiAm

    $BIOC - Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept'...

  • SoGiAm

    $CLLS long - Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adop...

  • Avatar

    $ONCS PBS News Hour Cancer Immunotherapy has Life Saving Powers and Limits https://www.pbs.org/newshour/show/cancer-immu...

  • Travis Johnson, Stock Gumshoe

    There's a lot of work being done to combine immunotherapy with radiation therapy, as well, with some real promise, from ...

  • Avatar

    I was hoping that the company mentioned would be doing something with immunotherapy. Instead of some machine frying me ...

  • Avatar

    $STML LONG NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage b...

  • Avatar

    ONCS (long as of yesterday) nice interview with CEO. First impression from his interview and body language is that he fe...

  • Avatar

    $TRIL Long Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developin...

  • SoGiAm

    $SNDX - Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Im...

  • SoGiAm

    $HTBX np - Heat Biologics Presents Follow-up Data on its ComPACT™ T-cell Stimulating Platform at the Society for Immun...

  • Avatar

    $ONCS LONG Dr. Alain Algazi will present the updated data in an oral poster presentation (P524) at the Society for I...

  • Avatar

    $ONCS LONG 10-Nov-17 Conferences SITC 32nd Annual Meeting Society for Immunotherapy of Cancer 2017 (ONCS...

  • Avatar

    $ONCS OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer I...

  • Avatar

    $ONCS LONG .com: OncoSec to present results of multi-gene expression platorm at SITC meeting OncoSec Medical will p...

  • Avatar

    Doc, would not the great data yesterday from ONCS bold well for HTBX with their partnership with them to combine their i...

  • Avatar

    $ONCS - new publication “Restoration of natural killer cell anti-metastatic activity by IL-12 and checkpoint block...

  • Avatar

    $RXDX Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer...

  • Avatar

    $ONCS Analyst Event in National Harbor, MD OncoSec will host an analyst and investor event with clinical investigator...

  • Avatar

    $ONCS NP Have been looking at this all morning and was just going to ask you Doc, your take on it. OncoSec r...

  • Avatar

    $SNDX LONG More News 07-Nov-2017:08:00:00, Syndax to Present at the SITC 32nd Annual Scientific Meeting WAL...

  • SoGiAm

    $HTBX - November 11th, 17 - Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy o...

  • Avatar

    $TRIL Trillium Therapeutics to Present at Upcoming Scientific Conferences (5 presentations!!! November 6, 2017 ...

  • Avatar

    $Probiotic $Immunotherapy $Melanoma **A new MD Anderson study (11/3) “Tuning the Microbiome Improves Melanoma...

  • SoGiAm

    $FATE - Fate Therapeutics Announces Six Presentations At The 2017 ASH Annual Meeting Fate Therapeutics Reports Third ...

  • SoGiAm

    $PIRS and $AFMD - October 31st, 2017: Both companies present at the World Immunotherapy Congress in Basel. Both presen...

  • SoGiAm

    $CLRB and Z long - Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in...

  • Avatar

    $ HALO LONG Halozyme Therapeutics (HALO) announces the initiation of a multi-arm clinical trial evaluating PEGPH20,...

  • SoGiAm

    $HALO - Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder ...

  • Dr. KSS MD PhD

    I'm coming to you live from the MicroCap Conference at Essex House near Central Park. I just had a fascinating conver...

  • SoGiAm

    $capr dmd. Poster link MIA. 6mo PUL MIA. https://twitter.com/XsleepftLearner/status/915540626602590208 $CNCR Lonca...

  • SoGiAm

    $RXDX np - Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology ...

  • Avatar

    $Noticker. Interesting "puff piece" on influential husband/wife MD Anderson researchers in immunotherapy, one of whom p...

  • SoGiAm

    $TRIL - Novemberf 8- 12, 17 - Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbour, MD http://...

  • Avatar

    $ARGS-Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017...

  • Avatar

    $FATE Coverage resumed by Leerink with PT=$7 Fate Therapeutics resumed with an Outperform at Leerink Leerink anal...

  • Avatar

    $ARGS Press Release yesterday, September 6, 2017 Argos Announces First Dosing of HIV Patient with AGS-004 Derived fro...

  • Avatar

    https://globenewswire.com/news-release/2017/08/21/1090597/0/en/Argos-Therapeutics-Announces-Interim-Analysis-of-Phase-3-...

  • SoGiAm

    Unum Therapeutics - private - to Present at Wedbush PacGrow Healthcare Conference August 14, 2017 08:00 AM Eastern Day...

  • Avatar

    Immunotherapy treatment for Type 1 Diabetes. http://www.cbsnews.com/news/immunotherapy-treatment-shown-safe-in-type-1...

  • SoGiAm

    Identification of essential genes for cancer immunotherapy http://www.nature.com/nature/journal/vaop/ncurrent/full/natu...

  • Avatar

    $ Beat Melanoma Wanted to share that after two years of treatment, a family member’s melanoma lesions in her leg hav...

  • SoGiAm

    $HALO np - Halozyme Therapeutics has added a new press release to its web site. For full details please visit the Halozy...

  • Avatar

    $CLRB Hello Doc, I saw you musing on twitter recently about a potential application for Cellectar's phospholipid e...

  • Avatar

    $AFMD New publication on Affimed's TandAb (AFM-13)): a first-in-class tetravalent bispecific anti-CD30/CD16A antibody...

  • Avatar

    Dr. KSS - here's is what I know on my friend, Nabeel Qureshi's current status and treatment at MD Anderson. He was told ...

  • Avatar

    Good listen on overcoming immunotherapy resistance. http://noveltargets.com/2017/05/episode-17-overcoming-immunotherapy...

  • Avatar

    I belong to a group of fans that reads and suggests changes to novels of Mark Dawson, a British writer of 007 type ficti...

  • SoGiAm

    $FATE - June 4th - Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research wit...

  • SoGiAm

    $FATE long - Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-...

  • Anamorph

    Magbio: welcome to the Gummune. Good research and questions. I did a great deal of homework on Dhillon back in 201...

  • Avatar

    $BLRX -small long position From a March 27th news release: BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage bi...

  • Avatar

    $BLRX-NP JMP note: BioLineRx Ltd. (BLRX: $1.09; $64.5M market cap ) BioLineRx reports 4Q16 earnings results and the ac...

  • SoGiAm

    $FATE long - $FATE Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Ca...

  • SoGiAm

    $FATE - Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the...

  • SoGiAm

    $FATE long - Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Tra...

  • Dr. KSS MD PhD

    Thanks Scorpio for noting that for sicilia. I would add someone was commenting yesterday that of our recent long ideas, ...

  • Dr. KSS MD PhD

    $KITE will be first to FDA with BLA filing for CAR-T indication, but surprisingly Novartis is right on their heels: htt...

  • Avatar

    FYI - Immunotherapy biotech Jounce Therapeutics sets terms for $75 million IPO 1/17/17 Jounce Therapeutics, an ear...

  • Avatar

    $KITE long CAR T-Cell Therapy for Lymphoma Leads to Complete Remission in Phase I Trial Immunotherapy approaches ...

  • Avatar

    Regarding PTN ---one should look at other transactions---cannot ignore management and financial considerations 1) MEI...

  • Avatar

    Nice article on immunotherapy http://www.bionapcfa.com/2017/01/a-look-at-cancer-immunotherapy-and-some.html $BMY ...

  • Avatar

    To All, Someone posted yesterday that Fortress Bio, symbol FBIO, had success with CAR T cell immunotherapy, is that si...

  • Avatar

    Anecdotal evidence m of FBIO (fortress bio) treatment using genetically modified Car-T immunotherapy (stock up pre-marke...

  • Dr. KSS MD PhD

    Hi savinir: Welcome to Gumtown, and good of you to ask about these stocks. $HTBX is a firm local for me and one about...

  • SoGiAm

    oNKo-innate Retweeted Marseille Immunopole ‏@Immunopole 2h2 hours ago Combination in #cancerimmunotherapy: obviou...

  • Avatar

    A current Neeswek article on #KRAS in cancer immunotherapy TRACKING DOWN ONE OF CANCER'S DEADLIEST CULPRITS, THE RAS...

  • Avatar

    #KRAS #TILS #Immunotherapy: Original article in NEJM which the prior NYT article was based on. T-Cell Transfer Therap...

  • Avatar

    First successful case of Immunotherapy targeting #KRAS #TILs **1 Patient, 7 Tumors and 100 Billion Cells Equal 1 Str...

  • Avatar

    For a while $TRIL was my largest position. I sold much of it after “FortySeven” (aka Stanford University) presented...

  • Avatar

    #ATNM - - Today from Ray Blanco of Technology Confidential Report: Actinium Pharmaceuticals (NYSE: ATNM) has been the...

  • SoGiAm

    $BIOC long and so is this post: Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biop...

  • Avatar

    OMER's GPCR program could deliver different approach to cancer immunotherapy. Omeros is establishing a wide patent posit...

  • Avatar

    A good synopsis of a rapidly advancing field: collection of new findings, ideas and strategies from #ESMO held last mont...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch